title: Outcome of colorectal liver metastases.
abstract: OBJECTIVE
  To determine the median survival of colorectal liver metastatic (CRLM) patients treated at King Chulalongkorn Memorial Hospital over the past 10 years and to determine the outcome of the various treatment modalities (surgery, chemotherapy and supportive treatment).
  
  
  METHODS
  Between January, 1992 and December, 2001, 86 consecutive patients were recorded. Of whom 26 (30.23%) received liver resection, 39 (45.34%) received chemotherapy and 21 (24.41%) received supportive treatment. All the patients were followed up to December 31, 2001 or death. Survival was calculated by Kaplan-Meier method and studied for statistical differences between various treatment groups with Cox regression model. The 95% confidence intervals for median assessment were determined.
  
  
  RESULTS
  Overall survival of CRLM patients was 18 months. Significant differences in survival were seen among the three groups of patients. Median survival was 33 months in the liver resection group, 17 months in the chemotherapy group and 5 months in the supportive treatment group. Three-year survival in the liver resection group was 23% while it was 7.6% in the chemotherapy group. Type of treatment, primary tumor staging and extrahepatic metastasis were the three independent determinant factors of survival.
  
  
  CONCLUSIONS
  Survival of patients with colorectal liver metastases depends on the type of treatment. Liver resection is the best treatment which offers long term survival to the patients in selected cases.
authors.affiliation: Department of Surgery, Faculty of Medicine, Chulalongkorn University, Bangkok 10330, Thailand.
authors.forename: Boonchoo
authors.initials: B
authors.lastname: Sirichindakul
authors.forename: Supparerk
authors.initials: S
authors.lastname: Prichayudh
mesh_terms: D015179:Colorectal Neoplasms / Q000188:drug therapy / Q000401:mortality / Q000556:secondary* / Q000601:surgery; D005260:Female; D006498:Hepatectomy; D006801:Humans; D008113:Liver Neoplasms / Q000188:drug therapy / Q000401:mortality / Q000556:secondary* / Q000601:surgery; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D011379:Prognosis; D016019:Survival Analysis